Endocrine Abstracts

Introduction: In diabetology all the recommendations insist on the intensification of the antidiabetic treatment with the maintenance of the same treatment if the type 2 diabetes mellitus is balanced. Our work insists on dietary treatment and focuses on weight loss in order to degress antidiabetic treatment until cessation.

Patients and methods: This is a prospective interventional study. Type 2 diabetes mellitus on pharmacological treatment: treatment is reduced if HbA1c ≤ 6.5%, until treatment is stopped in order to integrate the study. Type 2 diabetes mellitus without pharmacological treatment are monitored quarterly for 24 months, based on weight, fasting blood sugar and HbA1c.

Results: Our work brought together 289 patients with a sex ratio of 0.85 and an average age of 52 years and an average BMI of 29.6 kg/m², the average duration under antidiabetic treatment is 15 months, 74% under mono or dual therapy, 4 patients on insulin. 4% refused to stop treatment, 20% failed to stop treatment, 71% are still without pharmacological treatment, of which 49% exceeded 12 months and 20% exceeded 24 months. During the 24 months of follow-up: the average weight loss compared to the initial weight varied between −3 kg and −4.4 kg, the average fasting blood sugar varied between 1.10 and 1.19 g/l and HbA1c varied between 6.1% and 6.4%

Conclusion: As the intensification of the antidiabetic treatment is essential in the management of the patients with type 2 diabetes mellitus, the degression must be integrated into the therapeutic strategy in order to preserve the pancreatic capital and ensure a better quality of life.